The mechanism of tumor-associated hypoglycemia was examined in 11 patients with hepatocellular carcinoma, 6 of whom presented with severe hypoglycemia and 5 in whom plasma glucose was persistently normal. Serum insulin levels in the hypoglycemic patients were low. Although total serum insulinlike growth factor II (IGF-II) levels in both groups of tumor patients were lower than normal, tumor tissue from hypoglycemic patients contained levels of IGF-II mRNA that were 10-20-fold higher than those present in normal liver.
Introduction
It is well known that certain tumors may be associated with hypoglycemia. McFadzean and Yeung separated the occurrence of hypoglycemia in Chinese patients with hepatocellular carcinoma into two distinct types (1) . Patients with type A hypoglycemia developed mild reductions in plasma glucose which were readily treated, occurred during the terminal stages of the illness, and were associated with cachexia. In contrast, patients with type B hypoglycemia demonstrated marked decrements in glucose levels that were more difficult to control and that occurred in patients in whom cachexia was not a feature. Despite extensive study however, the factors responsible for the fall in blood glucose in the latter group of patients are unknown. Suggested causes include either decreased hepatic glucose production or increased glucose uptake either by the tumor or the periphery, or both (2, 3) .
Insulin levels have been consistently low in cases of tumor-associated hypoglycemia and, therefore, production of an insulin-like factor by the tumor has been suggested as the cause of the enhanced peripheral glucose uptake (4). Thus Megyesi et al. (5, 6) , Hyodo et al. (7) , and Gorden et al. (8) , using a radioreceptor assay (RRA),' identified increased serum nonsuppressible insulin-like activity (NSILA) in patients presenting with various tumors associated with hypoglycemia. It is now known that this receptor assay detects primarily IGF-II, and Daughaday et al. found elevated serum IGF-II levels in 10 of 14 patients with this syndrome using a sensitive RRA (9) . However, Zapf et al. (10) and Widmer et al. ( 11) subsequently found no elevation in serum IGF-II levels in patients with tumor hypoglycemia using either an RRA or immunoassay (RIA). High concentrations of IGF-II were recently reported by Daughaday et al. (12) in an extract of a leiomyosarcoma associated with recurrent hypoglycemia. It is important that a large proportion of the IGF-II immunoreactivity was of higher molecular weight in both the tumor and the patient's serum, and higher than expected amounts of the corresponding mRNA were identified in tumor tissue. Although IGF-II circulates bound to serum proteins (13) (14) (15) and although total serum IGF-II levels did not decrease after removal of the tumor, tumor resection was associated with remission ofhypoglycemia and with decreased amounts of higher molecular weight IGF-II in serum.
In this report, we describe 11 patients with hepatocellular carcinoma including a group of 6 patients presenting with severe recurrent hypoglycemia (corresponding to the type B patients described above) and a group of 5 who were normoglycemic. The availability of limited amounts of tumor and serum from these patients enabled us to determine if there were factors specific to the hypoglycemic group that might account for the low blood glucose. Studies involving analysis of tumor IGF-I1 mRNA and gel filtration of IGF-II immunoreactive peptides extracted from serum in both groups of pa-tients, and characterization of IGF-II-related peptides from tumors of hypoglycemic patients, suggest a possible causal relationship between products of the IGF-II gene and tumor hypoglycemia.
Methods

Subjects
Clinical details of the 1 I male patients with hepatocellular carcinoma are shown in Table I . Their ages ranged between 14 and 72 yr, applicable treatment regimens varied from one patient to another. The presence of hypoglycemia resulted in neuropsychiatric manifestations including aggressive behavior, confusion, seizures, and coma. Diagnosis of the underlying tumor was made during the course of investigation into the cause of hypoglycemia. For the hypoglycemic patients, serum was collected during episodes of low plasma glucose. Blood samples were obtained from normoglycemic patients at random. Only a single serum sample was available from each patient. The plasma glucose levels in the hypoglycemic group ranged from 0.1 to 1.6 mmol/liter at the time of clinical presentation. These patients required continuous infusion of intravenous glucose in order to maintain plasma glucose levels within the normal range. Death occurred rapidly (2 d to 9 wk after presentation) in all the patients. In contrast, in the normoglycemic group, the average plasma glucose was > 4 mmol/liter and no episodes of hypoglycemia were observed. An additional 19-yr-old patient with omental hemangiopericytoma associated with hypoglycemia (plasma glucose 1.3 mmol/liter) was examined. The patient remained normoglycemic after resection of the tumor.
Tumors and adjacent nonneoplastic liver were obtained from the six hypoglycemic patients with hepatocellular carcinoma. Only tumor samples were available from the five normoglycemic patients. 30-40 g of tissue was collected from each subject. Liver tissue was obtained after partial hepatectomy or at necropsy < I h after death. Upon removal, the tissues were frozen immediately in liquid nitrogen and then stored at -70'C until analyzed. (22) . IGF-I levels were measured using a specific RIA after binding proteins had been extracted as previously described (23, 24). Growth hormone concentrations were measured by RIA (Serono Diagnostics, Norwell, MA). RIA of IGF-II was performed using recombinant human IGF-II, '25I-labeled IGF-II (Eli Lilly, Indianapolis, IN) and a monoclonal antibody to IGF-II (Amano, Troy, VA) in 0.5 ml of 0.1 M Tris, 0.05 M NaCl, and I mg/ml bovine serum albumin (pH 7.4) essentially as described (25), except that precipitation was performed by addition of an equal volume of 24% polyethylene glycol (8000) and 20 Ml 1% bovine gamma globulin (10 mg/ml buffer). Total IGF-II levels in acidextracted serum and tumor tissue were determined as previously described ( 12) . Gel filtration of tumor extracts and serum was performed as described ( 12 and lower molecular weight forms. The fractions corresponding to higher and lower molecular weight material were pooled separately and gel filtration was repeated for each pool. IGF-II immunoreactivity as well as optical absorbance at 275 nm was measured in each fraction. Fraction numbers 56, 64, and 70 from the resulting elution profile of higher molecular weight IGF-II material and fraction number 78 from the lower molecular weight profile were lyophilized and then further analyzed by reverse-phase HPLC in a gradient of 20-40% acetonitrile in triethylammonium phosphate buffer over 60 min as previously described (26). l-ml fractions were collected and IGF-I1 immunoreactivity was determined in each fraction.
IGF-II binding studies. The size and heterogeneity of serum proteins to which IGF-II binds was determined as follows. 50 Al of serum from two normal subjects and two patients (patients 4 and 5, Table I) was incubated with -100,000 cpm of '251I-IGF-II at 4°C for 12 h, and then gel filtered on a 0.9 X 90 cm Ultrogel AcA 44 column (IBF Biotechnics, Inc., Savage, MD). Samples were eluted with buffer (0.1 M Tris, 0.05 M NaCl, 1 mg/ml BSA, pH 7.4) at a flow rate of 8-10 ml/min, 0.5-ml samples were collected, and radioactivity was determined in a gamma counter. To determine the binding capacity of serum for IGF-II, increasing volumes of serum (0.1-50 Al) from three normal subjects and three patients with hypoglycemia (patients 4, 5, and 6, Table I ) were incubated with -12,000 cpm of 125I-IGF-II for 12 h at 4°C in 500 ,l buffer (0.1 M Tris, 0.05 M NaCl, 1 mg/ml BSA, pH 7.4). Bound IGF-II was precipitated with an equal volume of 24% polyethylene glycol (8000) and 20 ,l of 1% bovine gamma globulin. Experiments were performed in duplicate.
For analysis of the affinity of IGF-II for serum binding proteins, sera from three normal, healthy subjects (1 Ml) and three patients with hypoglycemia (patients 4, 5, and 6, Table I, 2 Ml) were incubated with -12,000 cpm of '251I-IGF-II and progressively increasing concentrations of IGF-II (0.1-100 ng) in 500 Ml of the buffer described above. Bound radioactivity was precipitated as described above. To analyze the interactions of serum binding proteins with the various molecular forms of IGF-II detected in tumor extracts, fraction numbers 56, 64, and 70, which represent different regions ofthe large molecular weight IGF-II immunoreactivity profile (Fig. 3 a) , and fraction number 78 from the small molecular weight profile (Fig. 3 b) were lyophilized and dissolved in buffer. I Ml of serum from a healthy individual or 2 Ml of patient serum (patient 6, Table I ) was incubated with progressively increasing concentrations of IGF-II immunoreactivity (0.1-50 ng), assessed by RIA of these four fractions, after extraction of immunoreactive components into buffer, or IGF-II in the presence of -12,000 cpm '25I-IGF-II in a volume of 500 Ml buffer. After incubation at 4°C for 12 h, bound radioactivity was precipitated as described above.
Analysis ofIGF-II mRNA. IGF-I1 mRNA levels were specifically elevated 10-20-fold in tumor tissue from all the patients with hypoglycemia, compared to normal adult liver or adjacent noninvolved liver tissue (Fig. 1) . (Although IGF-II mRNA levels were also slightly elevated in the adjacent liver samples from hypoglycemic patients 1 and 6, reevaluation of these samples revealed microscopic infiltration by tumor cells). In contrast, IGF-I1 mRNA levels in tumors from normoglycemic patients were 0.1-1.3-fold of the level observed in normal adult liver. IGF-I and liver glucose transporter mRNA levels were increased -10-fold each compared with normal adult liver in one subject with hepatocellular carcinoma and hypoglycemia (patient 5, Table I ). The serum IGF-I concentration in this patient was 48 Mg/liter. Liver glucose transporter mRNA levels were also increased two-to threefold in patient 3 ( Table I Results Insulin, GH, and IGF-I concentrations. Serum insulin levels in the hypoglycemic patients were suppressed, and in four of the patients, were below the sensitivity of the assay (Table I) . The low insulin levels were appropriate for the prevailing plasma glucose levels, suggesting an alternative cause for the hypoglycemia. Patients who were normoglycemic had variable serum insulin levels, ranging from 7 to 179 pmol/liter. GH levels in four patients with hypoglycemia (subjects 3, 4, 5, and 6, Table I) were 15.4, 7.2, 6.3, and 2.7 mU/liter, respectively (normal, < 10 mU/liter) and GH levels in four patients who were normoglycemic (subjects 7, 8, 9, and 11, Table I) were 1.5, 0.4, 0.6, and 28.0 mU/liter, respectively. Insufficient serum was available for determination of GH concentrations in the other patients. Serum IGF-I levels were similar in both groups of patients with hepatocellular carcinoma, averaging 22±5 ,g/ liter and 29±9 ug/liter for the hypoglycemic and normoglycemic groups, respectively (normal range 150-480 ug/liter). IGF-II transcripts in the hepatocellular carcinomas and the hemangiopericytoma associated with hypoglycemia appeared to be similar to those in tumors from normoglycemic individuals and identical in size to those present in placenta. Since the IGF-II mRNA from several of the hypoglycemic tumors was heterogeneous, indicating that it may have been partially degraded, the abundance of IGF-II mRNA in normal liver and hypoglycemic tumor tissue was also determined using an RNase-protection assay (Fig. 2) . The increased abundance of IGF-II mRNA transcripts present in tumor tissue (relative to healthy liver) was similar in the RNase-protection and slot blot assays. This result thus confirms that specific IGF-II mRNA is indeed elevated in tumors from hypoglycemic patients. Analysis ofIGF-II immunoreactivity. Total IGF-II immunoreactivity in serum obtained from the patients with hepatocellular carcinoma who were hypoglycemic was 363±62 sg/ liter (range 179-568 gg/liter); values for those who were normoglycemic were 112±32 jig/liter; (range 46-217 jig/liter).
Although the difference between IGF-II levels in the two groups was statistically significant (P < 0.05), the levels in both groups were less than normal (normal range 330-1,080 ,ug/ liter, see reference 12). Gel filtration of serum samples by standard methods (12) demonstrated considerable size heterogeneity of the IGF-II immunoreactivity, a result consistent with previous findings in a patient with a leiomyosarcoma and hypoglycemia (12) . In patients who had hepatocellular carcinomas associated with hypoglycemia 48-72% of the serum IGF-II immunoreactivity eluted earlier than the mature IGF-II 7.5 kD standard suggesting the presence of a larger molecular weight form of IGF-II. In patients with hepatocellular carcinoma who were normoglycemic 6-40% of IGF-II immunoreactivity eluted as larger forms. Gel filtration of normal serum revealed no detectable higher molecular weight IGF-II immunoreactivity.
Total IGF-II concentrations measured on extracts of tumors from patients with hepatocellular carcinoma were 130±33 ng/g (range, 30-264 ng/g) and 22±2 ng/g (range, 16-28 ng/g) in the hypoglycemic and normoglycemic groups, respectively. Gel filtration of these tumor extracts demonsti'ted that the IGF-II immunoreactivity was similarly heterogeneous in size. To define the nature of IGF-II immunoreactivity identified by gel filtration in greater detail, the immunoreactivity eluting as larger and smaller molecular weight forms, from the tumors of four patients (1, 2, 5, and 6, a total of 100 g tumor), was pooled and gel filtration was repeated separately for these small and large molecular weight forms. Fig. 3 illustrates the resulting IGF-II immunoreactivity measured in the gel-filtered fractions. The immunoreactive profile observed after gel filtration of the larger molecular weight form revealed the presence of at least three major components, whereas the elution profile of the smaller molecular weight form appeared to be homogeneous. It is important that (a) even the highest molecular weight component was well separated from that region of the gel filtration profile in which IGF binding proteins would be expected to elute, and (b) our use of polyethylene glycol precipitation during RIA precluded the erroneous assessment of IGF-II/binding protein complexes as IGF-II immunoreactivity in the inhibition assay. Calibration of the column with standard proteins suggested that the higher molecular weight forms of IGF-II had molecular weights in the range 10,000-17,000.
To analyze further these different molecular forms of IGF-II, fraction numbers 56, 64, and 70 from the profile in Fig. 3 a and fraction number 78 from the profile represented in Fig. 3 b were examined by reverse-phase HPLC. Although the peptides sometimes eluted as broad peaks indicative of heterogeneity, all of these components eluted near the IGF-II standard, even during use of a shallow acetonitrile gradient (date not shown). It would therefore appear that either the carboxyl-terminal extensions expected on IGF-II precursors and conversion in- termediates do not interact with the hydrophobic column or that the mixture of hydrophobic and hydrophilic residues in these extensions are in approximate balance relative to the remainder of IGF-II. Analysis of IGF-JI interactions with serum proteins. To investigate the characteristics ofserum IGF-II binding proteins obtained from patients with hypoglycemia, serum that had been incubated with '25I-IGF-II was examined by gel filtration. Fig. 4 shows the results of these experiments in two patients and two normal subjects. As can be seen, the profiles obtained from patients and normal subjects were similar. Whereas a small fraction of bound radioactivity eluted in the void volume, the majority of bound radioactivity eluted at a position suggesting interaction ofIGF-II with a -30-40000-D binding protein. Small amounts of unbound IGF-II were also seen. It should be noted that the profile obtained from the serum of a third patient exhibited a broader and less well defined peak of '25I-IGF-11/binding protein complex after gel filtration. Control studies showed, however, that broad profiles were sometimes seen even in serum from normal subjects when serum had been stored for long periods.
We next undertook to analyze serum IGF-II binding ca- relative affinities of serum binding proteins from patients and normal subjects for IGF-II. Fig. 6 a illustrates that progressively increased concentrations of IGF-II competed for 125I-IGF-II binding equally in both patients' and normal serum, with 50% displacement occurring after the addition of 1-2 ng IGF-II and total displacement occurring after the addition of 20-100 ng.
Since the binding characteristics of patient and control serum for IGF-II were similar, the affinity of serum binding proteins for the various higher molecular forms of IGF-II identified in tumor extracts was determined. Fig. 6 b illustrates that IGF-II-related peptides recovered from fractions 64 and 70 from the larger molecular weight profile (Fig. 3 a) and from fraction 78 in the smaller molecular weight profile (Fig. 3 b) bound to serum with similar affinities (on the basis of immunometric equivalency), and that the competition profiles in fact did not differ from the profile obtained by use ofauthentic IGF-II. For these samples, 50% of radioactivity bound in the absence of competitor was displaced by -I ng of immunometrically quantified IGF-II-related material. In contrast, the IGF-II recovered from fraction 56 (which represented the highest molecular weight form ofrecovered IGF-II immunoreactivity) demonstrated negligible binding to serum proteins, whether the peptide was incubated with serum from normal subjects or hypoglycemic patients. Indeed, even after the addition of 20 ng of IGF-II immunoreactivity, less than 20% of bound radioactivity was displaced. Importantly, the equivalent amount of lower molecular weight forms resulted in almost complete inhibition of binding of radiolabeled IGF-II to serum binding proteins. tumor itself or by the periphery. The identification therefore that IGF-II expression is associated with the development of tumor hypoglycemia, has led to the suggestion that this peptide is important in the pathogenesis of this syndrome, and may mediate the development of hypoglycemia (12 To understand the potential relationship between IGF-II and the syndrome oftumor-associated hypoglycemia, two important factors regarding the physiology of this peptide should be borne in mind. First, IGF-II undergoes non-covalent binding to several serum binding proteins with an affinity constant approximately between 0.1 and 1 nM (28, 29). In fact it has been estimated that less than 1% of total IGF-II circulates freely. Second, binding of IGF-II to its carrier proteins inhibits transport across capillaries and prevents access to cell surface receptors, thus rendering it metabolically inactive (30) (31) (32) . Therefore, although an association between enhanced IGF-II expression in tumors associated with hypoglycemia has been made, (a) levels in serum have not been elevated above normal, (b) after resection of the tumor, serum levels may not be lower than those measured before operation, (c) free IGF-II in serum has not been detected in these patients, and (d) it is probable that the potency of IGF-II in producing hypoglycemia is low.
Although we have found no suggestion for differences in the character, functional binding capacity or affinity of serum binding proteins for IGF-II among hypoglycemic patients and normal subjects, the presence of higher molecular weight forms of IGF-II in the sera of hypoglycemic patients (reference 12 and this report) represents a matter ofconsiderable interest. Our demonstration of increased IGF-II expression in hepatic tumors of hypoglycemic patients, and our identification of higher molecular weight IGF-II immunoreactivity, which has a substantially reduced affinity for binding to serum binding protein, may explain the apparent paradox. These data suggest that a small proportion of this higher molecular weight IGF-II may circulate free under physiological circumstances, and thus may be available for interaction with cell surface receptors either in its native forms or after processing in the extracellular space. Although we could not measure free IGF-II levels in these patients due to the limited amount of serum available, the significance of this finding is highlighted by considering that if only 10% of total serum IGF-II immunoreactivity consisted of IGF-II with a negligible affinity for serum binding proteins, the peptide would circulate at a concentration of -40 ng/ml. A direct analysis of the abilities of these peptides to interact with cell-surface receptors that might play a role in glucose utilization must await an opportunity to obtain greater amounts of tumor or other tissue expressing the IGF-II gene.
Reduced affinity of IGF-II-related peptides for serum binding proteins may result either from the altered structure of a higher molecular weight IGF-II, such that its conformation precludes binding, or from proteolytic cleavage at a site important for interaction with binding proteins during metabolism to conversion intermediates. The sequence of higher molecular weight IGF-II-related peptides predicted from the cDNA project that there might be a variable degree of extension of the carboxyl terminus in these forms. On one hand cleavage at any ofa number ofpaired or single dibasic residues in the extended precursor peptide could account for the heterogeneous forms of IGF-II observed. On the other hand, small changes in the amino terminal region of IGF-I have been shown to decrease the affinity of ligand for the serum binding protein (33) . The characteristics ofthe higher molecular weight form of IGF-II with poor affinity for the binding protein could well arise from the simultaneous existence of a large carboxyl terminal extention and a short amino terminal deletion. Although insufficient amounts of material were available for furInsulin-like Growth Factor-II and Tumor Hypoglycemia 1677 ther characterization, we have found that all of these forms dilute in parallel in the IGF-II radioimmunoassay. Several similar peptides have been detected in the serum, tissue or cell culture medium (12, (34) (35) (36) (37) . Our results are consistent with those of Gowan et al. who showed that an unusual, intermediate molecular weight form of IGF-II isolated from human serum Cohn fraction IV associated with serum binding proteins with the same affinity as that exhibited by IGF-II itself (36). Although our analysis emphasizes interaction of IGF-II with the most available low molecular weight binding protein present in serum, several serum binding proteins with differing relative affinities for ligand and different half-lives are known to exist (27) . Further studies are therefore needed to address the full range of potential interactions of the various forms of IGF-II identified here with the multiple proteins to which they might bind in serum.
Whereas the low IGF-I levels in our patients are not readily explained, this finding has been reported in previous studies of tumor associated hypoglycemia (9, 12) . Although the suggestion has been made that low IGF-I levels are a consequence of suppressed growth hormone secretion, growth hormone levels were not demonstrated to be low in all of our patients. It is possible that their liver disease and altered nutritional state may have contributed to low IGF-I levels (38) .
To maintain plasma glucose at normal levels in patients with tumor hypoglycemia, daily glucose requirements of as much as 1.6 kg have been reported (1) . Since the normal rate of hepatic glucose output is -2-2.5 mg/kg per min (39, 40) , the hypoglycemia cannot result from reduced hepatic glucose output alone and glucose uptake must be increased to a substantial degree. However it remains to be seen whether the mechanism of hypoglycemia involves (a) stimulation of the insulin receptor, (b) stimulation ofthe IGF-I receptor, (c) stimulation of the IGF-II receptor or (d) another mechanism. Although analysis of the IGF system is made difficult both by the presence of serum binding proteins and by receptor crossreactivities, and although the pharmacodynamics of IGF action are, therefore, necessarily complex, our findings provide a mechanistic framework for the future consideration of the relationship between IGF-I gene expression and tumor hypoglycemia.
